Eledon Pharmaceuticals Inc (ELDN)

2026-06-25T11:05:47.000Z - 9 days ago

Natera, Eledon announce strategic partnership

NTRA

Jun 25, 2026, 7:00 AM EDT - 9 days ago

Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial

NTRA

Jun 22, 2026, 8:00 AM EDT - 12 days ago

Eledon Pharmaceuticals Transcript: Study result

Jun 22, 2026, 8:00 AM EDT - 12 days ago

Eledon Pharmaceuticals Press release: Study result

Jun 22, 2026, 8:00 AM EDT - 12 days ago

Eledon Pharmaceuticals Slides: Study result

2026-06-22T11:41:52.000Z - 12 days ago

Eledon Pharmaceuticals announces new long-term data from BESTOW program

Jun 22, 2026, 7:00 AM EDT - 12 days ago

Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus

2026-06-08T11:17:05.000Z - 26 days ago

Eledon Pharmaceuticals announces updated results from tegoprubart trial

Jun 8, 2026, 7:00 AM EDT - 26 days ago

Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine

Jun 4, 2026, 4:31 PM EDT - 4 weeks ago

Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions

May 20, 2026, 4:05 PM EDT - 6 weeks ago

Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress

2026-05-13T21:28:34.000Z - 7 weeks ago

Eledon Pharmaceuticals reports Q1 EPS (33c), consensus (23c)

May 13, 2026, 4:05 PM EDT - 7 weeks ago

Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 13, 2026, 4:00 PM EDT - 7 weeks ago

Eledon Pharmaceuticals Earnings release: Q1 2026

May 13, 2026, 4:00 PM EDT - 7 weeks ago

Eledon Pharmaceuticals Quarterly report: Q1 2026

2026-05-01T20:15:19.000Z - 2 months ago

Eledon Pharmaceuticals files $500M mixed securities shelf

May 1, 2026, 8:00 AM EDT - 2 months ago

Eledon Pharmaceuticals Registration statement: Registration filing

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Eledon Pharmaceuticals Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Eledon Pharmaceuticals Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 2 months ago

Eledon Pharmaceuticals Proxy statement: Proxy filing

2026-04-20T11:43:42.000Z - 2 months ago

NewcelX announces release of updated presentation on Type 1 Diabetes program

NCEL

Mar 19, 2026, 5:10 PM EDT - 3 months ago

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results

Mar 19, 2026, 4:00 PM EDT - 3 months ago

Eledon Pharmaceuticals Annual report: Q4 2025

Mar 19, 2026, 4:00 PM EDT - 3 months ago

Eledon Pharmaceuticals Earnings release: Q4 2025

2026-03-16T11:30:46.000Z - 3 months ago

Eledon announces updated data from islet transplant trial of tegoprubart

Mar 11, 2026, 1:40 PM EDT - 4 months ago

Eledon Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

2026-03-10T11:16:45.000Z - 4 months ago

Eledon Pharmaceuticals announces U.S. FDA granted ODD to tegoprubart

Mar 10, 2026, 7:00 AM EDT - 4 months ago

Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation

2026-03-09T11:12:39.000Z - 4 months ago

NewcelX announces research agreement with Eledon Pharmaceuticals

NCEL

Mar 9, 2026, 7:00 AM EDT - 4 months ago

NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes

NCEL

Mar 4, 2026, 4:05 PM EST - 4 months ago

Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference

Feb 12, 2026, 10:00 AM EST - 5 months ago

Eledon Pharmaceuticals Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 5, 2026, 4:10 PM EST - 5 months ago

Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

2026-01-23T12:05:49.000Z - 5 months ago

Eledon Pharmaceuticals presents long-term Phase 1b data for tegoprubart

Jan 23, 2026, 7:00 AM EST - 5 months ago

Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium

Jan 8, 2026, 4:05 PM EST - 6 months ago

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook

Dec 4, 2025, 8:50 AM EST - 7 months ago

Eledon Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 1, 2025, 7:00 AM EST - 7 months ago

Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference

2025-11-18T21:15:53.000Z - 8 months ago

Eledon Pharmaceuticals reports preliminary tegoprubart trial results

Nov 18, 2025, 4:05 PM EST - 8 months ago

Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

2025-11-18T11:35:08.000Z - 8 months ago

Eledon Pharmaceuticals price target lowered to $8 from $9 at Guggenheim

2025-11-14T22:05:10.000Z - 8 months ago

Eledon Pharmaceuticals reports Q3 EPS (21c), consensus (25c)

Nov 14, 2025, 5:00 PM EST - 8 months ago

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results

Nov 14, 2025, 4:00 PM EST - 8 months ago

Eledon Pharmaceuticals Earnings release: Q3 2025

Nov 14, 2025, 4:00 PM EST - 8 months ago

Eledon Pharmaceuticals Quarterly report: Q3 2025

Nov 12, 2025, 10:30 AM EST - 8 months ago

Eledon Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

2025-11-12T13:00:22.000Z - 8 months ago

Eledon prices 15.15M shares at $1.65 in underwritten public offering

Nov 12, 2025, 7:56 AM EST - 8 months ago

Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

2025-11-11T22:30:20.000Z - 8 months ago

Eledon Pharmaceuticals announces common stock, warrant offering, no amount given

Nov 11, 2025, 5:26 PM EST - 8 months ago

Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Nov 7, 2025, 8:00 AM EST - 8 months ago

Eledon Pharmaceuticals Transcript: Study Result

Nov 7, 2025, 8:00 AM EST - 8 months ago

Eledon Pharmaceuticals Press release: Study Result

Nov 7, 2025, 8:00 AM EST - 8 months ago

Eledon Pharmaceuticals Slides: Study Result

Nov 6, 2025, 6:30 PM EST - 8 months ago

Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology's Kidney Week 2025 Annual Meeting

Nov 5, 2025, 7:00 AM EST - 8 months ago

Eledon Pharmaceuticals to Present at Guggenheim Second Annual Healthcare Innovation Conference

Oct 17, 2025, 7:00 AM EDT - 9 months ago

Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting

Sep 24, 2025, 4:05 PM EDT - 10 months ago

Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association

Sep 5, 2025, 9:10 AM EDT - 10 months ago

Eledon Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Aug 29, 2025, 7:00 AM EDT - 11 months ago

Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025

Aug 14, 2025, 4:20 PM EDT - 11 months ago

Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results

Aug 14, 2025, 4:00 PM EDT - 11 months ago

Eledon Pharmaceuticals Quarterly report: Q2 2025

Aug 14, 2025, 4:00 PM EDT - 11 months ago

Eledon Pharmaceuticals Earnings release: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 11 months ago

Eledon Pharmaceuticals Transcript: Study Update

Aug 6, 2025, 4:30 PM EDT - 11 months ago

Eledon Pharmaceuticals Press release: Study Update

Aug 6, 2025, 4:30 PM EDT - 11 months ago

Eledon Pharmaceuticals Slides: Study Update

Aug 6, 2025, 4:01 PM EDT - 11 months ago

Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Jul 30, 2025, 4:05 PM EDT - 1 year ago

Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025

Jul 17, 2025, 4:01 PM EDT - 1 year ago

Updated Data from Eledon Pharmaceuticals' Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025

Jul 9, 2025, 8:30 AM EDT - 1 year ago

Eledon Pharmaceuticals Transcript: R&D Day 2025

Jul 9, 2025, 8:30 AM EDT - 1 year ago

Eledon Pharmaceuticals Slides: FY 2025

Jun 25, 2025, 4:01 PM EDT - 1 year ago

Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City

May 14, 2025, 4:01 PM EDT - 1 year ago

Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results

May 14, 2025, 12:00 AM EDT - 1 year ago

Eledon Pharmaceuticals Quarterly report: Q1 2025

May 14, 2025, 12:00 AM EDT - 1 year ago

Eledon Pharmaceuticals Earnings release: Q1 2025

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Eledon Pharmaceuticals Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Eledon Pharmaceuticals Proxy statement: Proxy Filing

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Eledon Pharmaceuticals Proxy statement: Proxy Filing

Apr 1, 2025, 7:00 AM EDT - 1 year ago

Eledon Pharmaceuticals Slides: Corporate Presentation

Mar 20, 2025, 4:01 PM EDT - 1 year ago

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results

Mar 20, 2025, 4:00 PM EDT - 1 year ago

Eledon Pharmaceuticals Annual report: Q4 2024

Mar 20, 2025, 4:00 PM EDT - 1 year ago

Eledon Pharmaceuticals Earnings release: Q4 2024

Mar 11, 2025, 2:20 PM EDT - 1 year ago

Eledon Pharmaceuticals Transcript: Leerink’s Global Healthcare Conference 2025

Mar 4, 2025, 4:05 PM EST - 1 year ago

Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference

Feb 7, 2025, 10:00 AM EST - 1 year ago

Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human

Feb 5, 2025, 1:00 PM EST - 1 year ago

Eledon Pharmaceuticals Transcript: Guggenheim SMID Cap Biotech Conference

Jan 29, 2025, 4:05 PM EST - 1 year ago

Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference

Jan 13, 2025, 7:00 AM EST - 1 year ago

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook

Nov 13, 2024, 1:30 PM EST - 1 year ago

Eledon Pharmaceuticals Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 12, 2024, 4:01 PM EST - 1 year ago

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results

Nov 12, 2024, 4:00 PM EST - 1 year ago

Eledon Pharmaceuticals Quarterly report: Q3 2024

Nov 12, 2024, 4:00 PM EST - 1 year ago

Eledon Pharmaceuticals Earnings release: Q3 2024

Oct 29, 2024, 7:46 AM EDT - 1 year ago

Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Oct 29, 2024, 7:45 AM EDT - 1 year ago

Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

Sep 20, 2024, 8:00 AM EDT - 1 year ago

Eledon Pharmaceuticals Registration statement: Registration Filing

Sep 11, 2024, 4:05 PM EDT - 1 year ago

Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference

Sep 4, 2024, 7:00 AM EDT - 1 year ago

Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients

Aug 14, 2024, 5:21 PM EDT - 2 years ago

Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results

Aug 14, 2024, 3:00 AM EDT - 2 years ago

Eledon Pharmaceuticals Quarterly report: Q2 2024

Aug 14, 2024, 3:00 AM EDT - 2 years ago

Eledon Pharmaceuticals Earnings release: Q2 2024

Jul 29, 2024, 7:00 AM EDT - 2 years ago

Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection

Jul 2, 2024, 4:05 PM EDT - 2 years ago

Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism

May 30, 2024, 8:00 AM EDT - 2 years ago

Eledon Pharmaceuticals Proxy statement: Proxy Filing

May 30, 2024, 8:00 AM EDT - 2 years ago

Eledon Pharmaceuticals Proxy statement: Proxy Filing

May 24, 2024, 8:00 AM EDT - 2 years ago

Eledon Pharmaceuticals Registration statement: Registration Filing

May 9, 2024, 4:00 PM EDT - 2 years ago

Eledon Pharmaceuticals Quarterly report: Q1 2024

May 9, 2024, 4:00 PM EDT - 2 years ago

Eledon Pharmaceuticals Earnings release: Q1 2024

May 9, 2024, 7:30 AM EDT - 2 years ago

Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results

May 9, 2024, 7:00 AM EDT - 2 years ago

Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress

May 7, 2024, 7:05 AM EDT - 2 years ago

Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection

Mar 28, 2024, 4:01 PM EDT - 2 years ago

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

Mar 28, 2024, 4:00 PM EDT - 2 years ago

Eledon Pharmaceuticals Annual report: Q4 2023

Mar 28, 2024, 4:00 PM EDT - 2 years ago

Eledon Pharmaceuticals Earnings release: Q4 2023

Mar 25, 2024, 4:56 PM EDT - 2 years ago

Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

Mar 21, 2024, 10:31 AM EDT - 2 years ago

Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human

Feb 13, 2024, 7:01 PM EST - 2 years ago

Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 4, 2024, 4:40 PM EST - 2 years ago

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook